Loading...
•
Dec 31, 2020
Stryker Q4 2020 Earnings Report
Stryker's Q4 2020 results reflected resilience amidst COVID-19 challenges, with net sales increasing by 3.2% and adjusted EPS rising by 12.9%.
Key Takeaways
Stryker reported a 3.2% increase in net sales to $4.3 billion for Q4 2020. Despite challenges from the COVID-19 pandemic, the company's adjusted EPS increased by 12.9% to $2.81. The Wright Medical integration is off to a strong start, and innovation continues across the company.
Net sales increased 3.2% to $4.3 billion.
Organic net sales decreased 1.1%.
Adjusted EPS increased 12.9% to $2.81.
The Wright Medical integration is off to a strong start.
Stryker
Stryker
Stryker Revenue by Segment
Revenue by Segment
MedSurg and Neurotechnology Revenue
CapyFin.comOrthopaedics Revenue
CapyFin.com Forward Guidance
Stryker expects 2021 organic net sales growth to be in the range of 8% to 10% from 2019 and adjusted net earnings per diluted share to be in the range of $8.80 to $9.20.
Positive Outlook
- Expects 2021 organic net sales growth to be in the range of 8% to 10% from 2019
- Expects adjusted net earnings per diluted share to be in the range of $8.80 to $9.20.
- Includes the previously announced 10 cents of dilution driven by the acquisition of Wright Medical for the full year.
- Assumes an ongoing recovery in our key geographies leading to more normalized elective procedure levels during the second quarter of 2021.
- Expect EPS will be modestly favorable for the full year if foreign currency exchange rates hold near current levels.
Challenges Ahead
- The impact on our operations and financial results of the COVID-19 pandemic and any related policies and actions by governments or other third parties
- Unexpected liabilities, costs, charges or expenses in connection with the acquisition of Wright
- Weakening of economic conditions that could adversely affect the level of demand for our products
- Pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products
- Potential supply disruptions
Revenue & Expenses
Visualization of income flow from segment revenue to net income